Catalent, Inc. (CTLT): Price and Financial Metrics

Catalent, Inc. (CTLT): $93.09

1.24 (+1.35%)

POWR Rating

Component Grades














  • CTLT scores best on the Growth dimension, with a Growth rank ahead of 74.83% of US stocks.
  • The strongest trend for CTLT is in Growth, which has been heading up over the past 179 days.
  • CTLT's current lowest rank is in the Quality metric (where it is better than 25.25% of US stocks).

CTLT Stock Summary

  • CTLT has a market capitalization of $16,005,318,383 -- more than approximately 88.23% of US stocks.
  • Price to trailing twelve month operating cash flow for CTLT is currently 36.46, higher than 87.67% of US stocks with positive operating cash flow.
  • For CTLT, its debt to operating expenses ratio is greater than that reported by 81.67% of US equities we're observing.
  • If you're looking for stocks that are quantitatively similar to CATALENT INC, a group of peers worth examining would be YUMC, MKC, PKG, RE, and DGX.
  • CTLT's SEC filings can be seen here. And to visit CATALENT INC's official web site, go to

CTLT Valuation Summary

  • In comparison to the median Healthcare stock, CTLT's EV/EBIT ratio is 150% higher, now standing at 27.
  • CTLT's price/sales ratio has moved up 2 over the prior 98 months.

Below are key valuation metrics over time for CTLT.

Stock Date P/S P/B P/E EV/EBIT
CTLT 2022-09-01 3.3 3.3 31.6 27.0
CTLT 2022-08-31 3.3 3.3 31.5 26.9
CTLT 2022-08-30 3.3 3.3 31.9 27.2
CTLT 2022-08-29 3.4 3.5 33.0 28.0
CTLT 2022-08-26 3.8 3.9 36.7 28.8
CTLT 2022-08-25 4.0 4.0 38.4 29.9

CTLT Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at 41.86%.
  • Its year over year price growth rate is now at -3.43%.
  • Its 3 year revenue growth rate is now at 89.83%.
CTLT's revenue has moved up $2,197,100,000 over the prior 33 months.

The table below shows CTLT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 4,828 439 503
2022-03-31 4,703.2 504.3 486.9
2021-12-31 4,483.5 441.3 563
2021-09-30 4,177.3 446.3 546.6
2021-06-30 3,998 433 529
2021-03-31 3,757.4 471.4 496.8

CTLT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CTLT has a Quality Grade of C, ranking ahead of 31.5% of graded US stocks.
  • CTLT's asset turnover comes in at 0.461 -- ranking 93rd of 682 Pharmaceutical Products stocks.
  • INSM, SPPI, and HSKA are the stocks whose asset turnover ratios are most correlated with CTLT.

The table below shows CTLT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.461 0.342 0.125
2021-06-30 0.469 0.338 0.131
2021-03-31 0.459 0.332 0.129
2020-12-31 0.447 0.323 0.086
2020-09-30 0.451 0.322 0.082
2020-06-30 0.456 0.318 0.073

CTLT Stock Price Chart Interactive Chart >

Price chart for CTLT

CTLT Price/Volume Stats

Current price $93.09 52-week high $142.64
Prev. close $91.85 52-week low $86.11
Day low $90.35 Volume 172,024
Day high $93.09 Avg. volume 1,205,467
50-day MA $104.58 Dividend yield N/A
200-day MA $106.67 Market Cap 16.75B

Catalent, Inc. (CTLT) Company Bio

Catalent provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It operates through three segments: Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The company was founded in 2007 and is founded in Somerset, New Jersey.

CTLT Latest News Stream

Event/Time News Detail
Loading, please wait...

CTLT Latest Social Stream

Loading social stream, please wait...

View Full CTLT Social Stream

Latest CTLT News From Around the Web

Below are the latest news stories about CATALENT INC that investors may wish to consider to help them evaluate CTLT as an investment opportunity.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nektar Therapeutics (NKTR), Catalent (CTLT) and Elevation Oncology (ELEV)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nektar Therapeutics (NKTR – Research Report), Catalent (CTLT – Research Report) and Elevation Oncology (ELEV – Research Report). Nektar Therapeutics (NKTR) Nektar Therapeutics received a Sell rating from J.P. Morgan analyst Jessica Fye yesterday. The company's shares closed last Tuesday at $4.03, close to its 52-week low of $3.02. According to TipRanks.

Howard Kim on TipRanks | August 31, 2022

Despite Price Cut, RBC Capital Is Bullish On Catalent's Long Term Targets

RBC Capital Markets cut the price target on Catalent Inc (NYSE: CTLT) from $155 to $125 with an Outperform rating. The analyst notes that the company reported mixed Q4 FY22 earnings as revenue was 1% below consensus and EBITDA 1.5% above. Related: Catalent Reports Mixed Q4 Earnings; FY23 Sales Expectation Lags Consensus. Adjusting for foreign exchange, EBITDA guidance did come in below consensus due to supply chain and inflationary pressures and lower expected capacity utilization as COVID busin

Yahoo | August 30, 2022

Catalent (CTLT) Stock Down Despite Q4 Beat: Will it Recover?

Catalent's (CTLT) fiscal fourth-quarter earnings beat but the stock falls 7.4% following the earnings release on Aug 29. Here we discuss the factors that are set to guide its share price going forward.

Yahoo | August 30, 2022

Company News for Aug 30, 2022

Companies in The News Are: HTHT,CTLT,MRNA,BA,UPS

Yahoo | August 30, 2022

Catalent (CTLT) Q4 2022 Earnings Call Transcript

Thank you for attending today's Catalent, Inc. fourth quarter fiscal year 2022 earnings call. Good morning, everyone, and thank you for joining us today to review Catalent's fourth quarter and full fiscal year 2022 financial results. Joining me on the call today are Alessandro Maselli, president and chief executive officer; and Tom Castellano, senior VP and chief financial officer.

Yahoo | August 29, 2022

Read More 'CTLT' Stories Here

CTLT Price Returns

1-mo -13.91%
3-mo -12.73%
6-mo -3.15%
1-year -34.60%
3-year 80.20%
5-year 130.71%
YTD -27.29%
2021 23.02%
2020 84.85%
2019 80.56%
2018 -24.10%
2017 52.37%

Continue Researching CTLT

Here are a few links from around the web to help you further your research on Catalent Inc's stock as an investment opportunity:

Catalent Inc (CTLT) Stock Price | Nasdaq
Catalent Inc (CTLT) Stock Quote, History and News - Yahoo Finance
Catalent Inc (CTLT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6264 seconds.